Table 2.

Risk of incident eGFR<60 ml/min per 1.73 m2, incident CKD, doubling of serum creatinine, ≥30% decline in eGFR, and ESRD, dialysis, or transplantation by monocyte count quartile

Outcome and MeasureMonocyte Quartile 1 >0.00 to ≤0.40 k/cmmMonocyte Quartile 2 >0.40 to ≤0.55 k/cmmMonocyte Quartile 3 >0.55 to ≤0.70 k/cmmMonocyte Quartile 4 >0.70 k/cmm
eGFR<60 ml/min per 1.73 m2a
 No. of events (%)95,830 (32.5)88,643 (34.0)114,906 (35.0)66,812 (35.2)
 Incidence rate per 100,000 person-yr (95% CI)4560.4 (4531.5 to 4589.2)4854.1 (4822.1 to 4886.0)5105.7 (5076.2 to 5135.3)5327.8 (5287.4 to 5368.2)
 HR (95% CI)1.001.02 (1.01 to 1.03)1.04 (1.04 to 1.05)1.13b (1.12 to 1.14)
Incident CKDc
 No. of events (%)56,419 (20.1)53,370 (21.4)69,306 (22.1)39,744 (22.1)
 Incidence rate per 100,000 person-yr (95% CI)2522.3 (2501.5 to 2543.1)2728.7 (2705.5 to 2751.8)2865.6 (2844.3 to 5887.0)2949.2 (2920.2 to 2978.2)
 HR (95% CI)1.001.03 (1.02 to 1.05)1.06 (1.05 to 1.07)1.15b (1.13 to 1.16)
Doubling of serum creatinine
 No. of events (%)30,463 (7.3)28,415 (7.4)38,885 (7.8)26,449 (8.9)
 Incidence rate per 100,000 person-yr (95% CI)900.4 (890.2 to 910.5)922.1 (911.4 to 932.8)988.2 (978.4 to 998.0)1184.1 (1169.9 to 1198.4)
 HR (95% CI)1.001.02 (1.00 to 1.04)1.07 (1.05 to 1.08)1.22b (1.20 to 1.24)
≥30% Decline in eGFR
 No. of events (%)123,897 (29.8)116,637 (30.5)157,895 (31.7)101,973 (34.3)
 Incidence rate per 100,000 person-yr (95% CI)4170.7 (4147.5 to 4193.9)4325.7 (4300.9 to 4350.5)4614.5 (4591.8 to 4637.3)5324.1 (5291.4 to 5356.7)
 HR (95% CI)1.001.02 (1.01 to 1.03)1.06 (1.05 to 1.07)1.18b (1.17 to 1.19)
ESRD, dialysis, or transplant
 No. of events (%)14,875 (3.6)13,576 (3.6)19,141 (3.8)13,427 (4.5)
 Incidence rate per 100,000 person-yr (95% CI)430.2 (423.3 to 437.1)430.7 (423.4 to 437.9)475.1 (468.3 to 481.8)584.7 (574.8 to 594.6)
 HR (95% CI)1.000.98 (0.96 to 1.00)1.04 (1.02 to 1.06)1.19b(1.16 to 1.22)
  • Models were adjusted for age, race, sex, cardiovascular disease, cerebrovascular accident, chronic lung disease, dementia, diabetes mellitus, hepatitis C, HIV, hypertension, hyperlipidemia, cancer, peripheral artery disease, and time zero eGFR. The referent category is monocyte quartile 1. k/cmm, 1000 cells per cubic millimeter; 95% CI, 95% confidence interval; HR, hazard ratio.

  • a Incident eGFR<60 ml/min per 1.73 m2 was evaluated in a subcohort of people with no prior history of eGFR≤60 ml/min per 1.73 m2 at time of cohort entry (n=1,074,166).

  • b P value for trend <0.001.

  • c Incident CKD was evaluated in a subcohort of people with at least two eGFRs separated by at least 90 days who had no prior history of eGFR≤60 ml/min per 1.73 m2 at the time of cohort entry (n=1,024,422).